Matthew Outten

Corporate Officer/Principal at BRIDGEBIO PHARMA, INC.

49 year

Health Technology

Consumer Services

Profile

Matthew Outten is currently the Chief Commercial Officer at QED Therapeutics, Inc. and also holds the position of Chief Commercial Officer at BridgeBio Pharma, Inc. He previously worked as the Vice President-Marketing & Marketing Access at Pharmacyclics LLC from 2013 to 2018.
Outten completed his undergraduate degree at Hamilton College (New York) and earned an MBA from the University of Delaware.

Matthew Outten active positions

Companies	Position	Start
BRIDGEBIO PHARMA, INC.	Corporate Officer/Principal	2019-01-31
QED Therapeutics, Inc. QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017.	Corporate Officer/Principal	-

All active positions of Matthew Outten

Former positions of Matthew Outten

Companies	Position	End
PHARMACYCLICS, INC.	Corporate Officer/Principal	-

See the detail of Matthew Outten's experience

Training of Matthew Outten

Hamilton College (New York)	Undergraduate Degree
University of Delaware	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Matthew Outten's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
BRIDGEBIO PHARMA, INC.	Health Technology

Private companies	2
Pharmacyclics LLC Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA.	Health Technology
QED Therapeutics, Inc. QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017.	Health Technology